Under Fire: Progenix Pharmaceuticals (PGNX, US7431871067) -50%
Und wieder ist eine Phase-III Studie in die Binsen gegangen… Die Aktie von Progenix Pharmaceuticals (PGNX, US7431871067) verliert vorbörslich über -50%.
Benutzerdefinierte Suche
Lesefutter 
(→ Archiv)
- Judge who overturned moratorium owned Transocean, Halliburton stock
- Spain plays high-stakes poker game with Germany as borrowing costs surge
- Rating-Riese stuft Griechen-Anleihen auf Ramschstatus herab
- Investors are betting on a Black Monday-style collapse, BoE warns
- Soros Says ‘We Have Just Entered Act II’ of Crisis
- U.S. Identifies Vast Riches of Minerals in Afghanistan
- SEC Signs Off On Stock Market ‘Circuit Breakers’
- Bono named worst investor in America
- Goldman Being Sued By Hedge Fund Over Toxic CDOs
- Euro ‘will be dead in five years’ – Telegraph